Half Year 2026 Mayne Pharma Group Ltd Earnings Call Transcript
Key Points
- Mayne Pharma Group Ltd (MAYNF) reported a gross margin increase to 65.3%, up from 61.4% in the prior corresponding period.
- The Dermatology segment showed significant profitability improvement with a 35% increase in direct contribution, driven by a favorable mix and channel strategy.
- Women's Health segment delivered solid top-line growth with products like NEXTSTELLIS, IMVEXXY, and BIJUVA showing strong demand and share gains.
- The company has a strong cash position, closing the half with $67.4 million in cash and marketable securities.
- Mayne Pharma Group Ltd (MAYNF) is in a strong position to capitalize on opportunities with a differentiated portfolio and clear strategic priorities across its segments.
- Underlying EBITDA was down 8% compared to the prior corresponding period, reflecting lower Women's Health contribution due to additional sales investment.
- The company faced significant legal and transaction costs, including $20.7 million in scheme-related transaction and litigation costs.
- ANNOVERA product returns impacted net sales, with a 9% decrease despite a 2% increase in TRx.
- The company is dealing with emerging competition for RHOFADE, with expected generic launches at the end of fiscal '26.
- Direct operating expenses increased by 7%, reflecting targeted investments, which impacted profitability.
Thank you for standing by, and welcome to the Mayne Pharma Group Limited half-year 2026 results webcast. Management apologizes for the late start today due to the release of the presentation to the ASX. (Operator Instructions)
And I'll to hand the conference over to Mr. Aaron Gray, CEO. Please go ahead.
Thank you. Good morning, everyone, and thank you for joining Mayne Pharma's 1H fiscal '26 results presentation. Today, we will cover the group financial outcome for the half then take you through each segment, Women's Health, Dermatology, and International, before finishing with our fiscal '26 focus and outlook. As investors will appreciate, we have already provided a set of our unaudited numbers within our presentation at the company's 2025 Annual General Meeting on January 29, 2026.
Before we begin the formal aspects of today's presentation, as we announced to the market this morning, Mayne Pharma is undertaking a planned and orderly leadership transition, with Shawn Patrick O
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
